Patients with chronic kidney disease and end-stage renal disease are at 5-to 10-fold higher
risk for developing cardiovascular disease (CVD) than age-matched controls. Clinically …

Background A significant proportion of cardiovascular disease (CVD) morbidity and mortality
could be prevented via the population-based and cost-effective interventions. A fixed-dose …

5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …

Background A Polypill is proposed for the primary prevention of cardiovascular disease in
people judged to be at risk on account of their age alone. Its efficacy in reducing cholesterol …

Non-communicable diseases are the leading global causes of mortality and morbidity.
Growing pressures on health services and on social care have led to increasing calls for a …

Background To assess the blood pressure and lipid-lowering efficacy and tolerability of
'polypills' used in cardiovascular disease prevention trials. Methodology/Principal Findings …

Prevention of non-communicable disease: best buys, wasted buys, and contestable buys | The
BMJ Skip to main content Intended for healthcare professionals Access provided by Google …

The content of these European Society of Cardiology (ESC) and European Atherosclerosis
Society Guidelines has been published for personal and educational use only. No …

5.1. Wpływ stylu życia na stężenie cholesterolu całkowitego i stężenie cholesterolu frakcji
lipoprotein o małej gęstości................................ 1259 5.2. Wpływ stylu życia na stężenie …

Introduction Combination therapies continue to improve therapeutic outcomes as currently
achieved by polypharmacy. Since the introduction of the polypill, there has been a …